Robust isolation of malignant plasma cells in multiple myeloma.
Författare
Summary, in English
Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma (MM). However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and evaluated seven candidates systematically. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138, and enable isolation of myeloma plasma cells under more diverse conditions, including in samples that have been delayed or frozen. Our results form the basis of improved procedures for characterizing cases of multiple myeloma in clinical practice.
Avdelning/ar
- Hematogenomics
- Myelomgruppen
- Avdelningen för hematologi och transfusionsmedicin
- Avdelningen för klinisk genetik
- Institutionen för kliniska vetenskaper, Malmö
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
Publiceringsår
2014
Språk
Engelska
Sidor
1336-1340
Publikation/Tidskrift/Serie
Blood
Volym
123
Issue
9
Länkar
Dokumenttyp
Artikel i tidskrift
Förlag
American Society of Hematology
Ämne
- Hematology
Status
Published
Projekt
- Genetic predisposition for multiple myeloma
Forskningsgrupp
- Hematogenomics
- Myeloma research group
ISBN/ISSN/Övrigt
- ISSN: 1528-0020